SB 061

Drug Profile

SB 061

Alternative Names: SB061

Latest Information Update: 01 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SYMIC Biomedical
  • Developer Nordic Bioscience; SYMIC Biomedical
  • Class Proteoglycans
  • Mechanism of Action Cartilage replacements; Proteoglycan replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Osteoarthritis

Most Recent Events

  • 31 Jul 2017 Symic initiates enrolment in the MODIFY2 phase I trial for Osteoarthritis in Estonia before July 2017 (NCT03231280)
  • 01 Jun 2017 Symic completes the MODIFY-OA phase I/II trial in Osteoarthritis in Estonia (Intra-articular) (NCT02802709)
  • 18 May 2017 Efficacy and safety data from the phase I/IIa MODIFY-OA trial in Osteoarthritis released by Symic Bio
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top